Manteio Capital’s Seres Therapeutics MCRB Stock Holding History

Manteio Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,499	Closed	-$250K	–	126
2021 Q4	$250K	Buy	+1,499	New	+$238K	0.32%	134

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Manteio Capital's MCRB Position: Q1 2022 in Review

Manteio Capital sold out of Seres Therapeutics (MCRB) in Q1 2022, closing a stake of 1,499 shares — an estimated $250K sold.

Manteio Capital first reported a position in MCRB in Q4 2021 and held it in 1 quarter. The position peaked at $250K in Q4 2021. 131 funds tracked by Wall St. Rank hold MCRB as of Q1 2022.

Manteio Capital reported no remaining Seres Therapeutics position as of Q1 2022 after selling out during the quarter.
Manteio Capital sold 1,499 Seres Therapeutics shares in Q1 2022, an estimated $250K.
Manteio Capital first reported a position in Seres Therapeutics in Q4 2021 and held it in 1 quarter.
Manteio Capital's Seres Therapeutics position peaked at $250K in Q4 2021.
131 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2022.

Based on Manteio Capital's 13F filing for Q1 2022.